Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 1/20 | 0.48 |
| ▸ | TUBB known ✓ | P07437 | 1/20 | 0.48 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 1/20 | 0.48 |
| ▸ | TUBA1B known ✓ | P68363 | 1/20 | 0.48 |
| ▸ | TUBA4A known ✓ | P68366 | 1/20 | 0.48 |
| ▸ | TUBB4B known ✓ | P68371 | 1/20 | 0.48 |
| ▸ | TUBB3 known ✓ | Q13509 | 1/20 | 0.48 |
| ▸ | TUBB2A known ✓ | Q13885 | 1/20 | 0.48 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 1/20 | 0.48 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 1/20 | 0.48 |
| ▸ | TUBA1A known ✓ | Q71U36 | 1/20 | 0.48 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 1/20 | 0.48 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 1/20 | 0.48 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 1/20 | 0.48 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 1/20 | 0.48 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259375 | 0.96 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL4262320 | 0.96 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| Hydrochloric Acid SCHEMBL4258508 | 0.96 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL4255742 | 0.90 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL4259379 | 0.90 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL6079420 | 0.88 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL6078155 | 0.88 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL4254654 | 0.87 | KDM4E (0.39) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL4257316 | 0.87 | KDM4E (0.39) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL4258726 | 0.83 | KDM4E (0.52) | KDM4EALDH1A1HPGDHSD17B10ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1486500-B1 | 10-(3-CYCLOPROPYLAMINOMETHYL-1-PYRROLIDINYL)PYRIDOBENZOXAZINECARBOXYLIC ACID DERIVATIVE EFFECTIVE AGAINST RESISTANT BACTERIA | KYORIN SEIYAKU KK (JP) | 2009-09-16 | — | — | EP | disclosed |
| US-7153851-B2 | 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20050182052-A1 | 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1486500-A1 | 10-(3-CYCLOPROPYLAMINOMETHYL-1-PYRROLIDINYL)PYRIDOBENZOXAZINECARBOXYLIC ACID DERIVATIVE EFFECTIVE AGAINST RESISTANT BACTERIUM | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182052-A1 | 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium | RRP15, RRP12, RRS1 | TUBB4A 4540/4885TUBB 3865/4885TUBA3C 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.